CMTx Biotech

Executive Summary

CMTx Biotech, Inc. is a private, preclinical-stage biotechnology company based in Cambridge, MA, focused on developing host-directed therapeutics (HDTs) against high-priority chemical, biological, radiological, and nuclear (CBRN) threats and infectious diseases. Founded in 2019, the company employs a unique strategy of rescuing, repurposing, and reformulating existing clinical-stage or approved small molecule drugs to accelerate development timelines and reduce risk. By leveraging known safety profiles, CMTx aims to rapidly advance medical countermeasures into clinical testing. The company's pipeline remains in early preclinical stages, with potential for near-term milestones including IND-enabling studies and initial Phase 1 trial designs. Given the urgent need for CBRN countermeasures and CMTx's capital-efficient approach, the company represents an attractive early-stage investment opportunity with government funding potential.

Upcoming Catalysts (preview)

• Q4 2026Completion of IND-enabling toxicology studies for lead HDT candidate70% success
• H1 2026Announcement of strategic partnership or government contract (e.g., BARDA or NIH)40% success
• Q2 2027Initiation of first-in-human Phase 1 trial for lead asset50% success